Grants, Contracts And Awards To Biotech Companies: Dec. 1, 2005-March 22, 2006
Company* | Funding | Amount | Type# | Details (Date) |
Advanced | National Institute of Neurological Disorders and Stroke | ND | Phase I SBIR grant | Funds will support preclinical testing of the small molecule ALS-886 to reduce brain swelling leading to tissue damage following a stroke (2/7) |
Advanced | Australian government | A$1.4 ($1) | Commercial Ready grant | The funding will be provided over three years to match company funding and be used to support development (3/1) |
Alba | Maryland Industrial Partnerships | ND | Funding support | Funds will go toward completion of work on zonulin receptor cloning and characterization (2/21) |
Alba | National Institute of Diabetes, Digestive and Kidney Diseases | ND | SBIR grant | The grant will support development of Alba's lead molecule, AT-1001, for treating Type I diabetes (2/21) |
Alnylam | U.S. Department of Defense | ND | Funding support | The funds will support development of RNAi therapeutics for pandemic influenza (12/14) |
Arteriocyte Inc.* | National Institutes of Health | $1.4 | STTR grant | Funds will support a Phase I trial evaluating the safety of adult- derived hemangioblasts to treat chronic ischemia (1/19) |
Atom Sciences | National Institutes of Health | $0.6 | Grant | Funds will support development of a technology for rapid identification of disease pathogens in case of a biowarfare attack or a major outbreak(2/10) |
AVI BioPharma | Department of Defense | $11 | Defense appropriation | FY2006 appropriation bill includes $11M to fund ongoing programs studying Neugene technology for Ebola, Marburg and dengue viruses, and anthrax and ricin countermeasures (1/4) |
BiondVax Pharmaceuticals* (Israel) | Israeli government | $1.1 | Funding support | Funds will support development of its five-year, nasally administered, universal influenza vaccine (12/22) |
Biopure Corp. | U.S. Navy | $4 | Defense | FY2006 appropriations bill includes $4M in funding for the Navy to continue studying the use of Hemopure in trauma applications (1/3) |
Biota Holdings | National Health and Medical Research Council (Australia) | A$0.09 ($0.065) | Grant | Funds will support studies on a long-acting neuraminidase inhibitor against several avian flu strains (2/20) |
Bioxel Pharma | Natural Sciences and Engineering Research Council of Canada | C$0.273 ($0.234) | Funding support | The funding is to support formuation development of anticancer drugs; it will take the form of a grant, with installments paid upon completion of development milestones (12/16) |
Blue Heron | National Institute of General Medical Science and the National Human Genome Research Institute | $0.77 | Phase II SBIR grant | The grant will fund research to develop methods for assembling very large recombinant DNA molecules (3/13) |
Cepheid Inc. | Canadian government | C$0.78 ($0.69) | Grant | Cepheid and the Public Health Agency of Canada's National Microbiology Laboratory will use the funds to develop assays for Ebola, Marburg and Lassa fever viruses (2/14) |
Chaperone | U.S. Army | $1 | Defense appropriation | Chaperone, Lackawanna College and the University of Scranton will use the funds to develop methods for destroying drug-resistant bacteria (1/25) |
Chiron Corp. | UK government | ND | Contract | Contract calls for Chiron to supply the UK government pre-pandemic influenza vaccine for a stockpile based on the H5N1 avian influenza virus strain (2/24) |
CombiMatrix | Department of Defense | $2.1 | Contract | Conrtact focuses on integrating CombiMatrix's microarray technology with microelectronics and microfluidics to develop a system for detecting biothreats (2/13) |
CombiMatrix | Department of Defense | $2.4 | Defense appropriation | Funds will support further development of microarray technologies for detecting biological and chemical threat agents (1/17) |
Compugen Ltd. | European Commission | €3.1 ($3.7) | Funding support | Compugen is leading a consortium to develop a platform to simulate the cancer-related MAP kinase pathway; the consortium also includes Aureus Pharma and several institutions (3/7) |
Copernicus | Cystic Fibrosis Foundation Therapeutics Inc. | $1.5 | Funding support | The $1.5M in 2006 funding will support development of a gene therapy for CF; another $4.6M could be paid in 2007 if progress continues (2/14) |
GenVec Inc. | National Institute of Allergy and Infectious Diseases | $0.3 | Subcontract funding | Funds will support preliminary vector development in preparation for the manufacture of clinical-grade adenovector-based influenza vaccines (2/9) |
Iceland Genomics | European Union | ND | Sixth Framework Program award | A consortium including IGC, Bioinformatics ApS, University of Oxford and Radboud University will study the inherited risk of breast and prostate cancers (12/19) |
Illumina Inc. | National Cancer Institute | ND | Subcontract award | Illumina will perform whole- genome SNP scans on more than 2,500 prostate case and control samples, in support of the NCI's Cancer Genetic Markers of Susceptibility program(2/14) |
Invitrogen | Department of Defense | $0.97 | Contract award | Invitrogen Federal Systems will use the funding to produce and validate protein microarrays to biothreat agents (1/10) |
Iomai Corp. | National Institute of Allergy and Infectious Diseases | $1.4 | Grant | Funds will support development of an immunostimulant needle-free patch to extend availability of stocks of influenza vaccine in the case of a pandemic (3/9) |
Juvaris | National Institute of Allergy and Infectious Diseases | ND | SBIR-Advanced Technology grant | The 18-month grant will support testing of an HIV vaccine that uses Juvaris' JuvaVax vaccine platform (3/7) |
Juvaris | National Institute of Allergy and Infectious Diseases | ND | STTR grant | Juvaris and Stanford University will work on a next-generation influenza A vaccine, with an emphasis on avian influenza (1/9) |
Lentigen Corp. | Maryland's Department of Business and Economic Development | ND | Challenge Investment Program funding | The funding will support development of the company's lenti-viral technology (12/13) |
MaxThera Inc. | National Institute of Allergy and Infectious Diseases | $0.6 | Phase I SBIR grant | Two-year grant will support effort to design and develop antibiotics for infections complicated by antibiotic resistance (2/1) |
Medarex Inc. | Department of Defense | $2.05 | Defense appropriation | The funding will support development of Valortim, a fully human antibody being developed to prevent and treat anthrax infection (1/10) |
MNLpharma Ltd.*, | Department of Trade and Industry (UK) | £1.5 ($2.6) | Grant | The three-year matching grant will support development of a room- temperature, stable, controlled-release vaccine technology (3/17) |
Nanotrope | National Aeronautics and Space Administration | $0.6 | Phase II SBIR grant | Funds will support development of nanoscale technology for new drug formulations and delivery protocols (2/3) |
Northfield | Department of Defense | $3.5 | Defense appropriation | FY2006 appropriations bill includes $3.5M for continued development of PolyHeme, the company's hemoglobin-based oxygen carrier (1/3) |
Novavax Inc. | National Institute of Allergy and Infectious Diseases | $1 | Funding support | The additional money will fund the third year of a 4.5-year research program focused on an HIV/AIDS virus-like particle vaccine (3/16) |
PolyMedix Inc.* | National Institute of Allergy and Infectious Diseases | $3 | Phase II SBIR grant | Funds will be used to identify a lead compound and backups for an intravenous antibiotic to treat hospital-acquired infections (3/21) |
Procyon | National Research Council Canada | $0.98 | Industrial Research Assistance Program contribution | The repayable contribution will support development of the pro-tease inhibitor PPL-100 for treating drug-resistant HIV (1/13) |
ProlX | National Cancer Institute | $5.6 | National Cooperative Drug Discovery Group award | ProlX and four research institutions got the five-year award to discover therapies that target cells while minimizing damage to normal, healthy cells (12/7) |
ProteoTech Inc.* | Michael J. Fox Foundation for Parkinson's Research | $3.1 | Funding award | ProteoTech and collaborators will get up to $3.1M for work on a PD therapy that can disrupt or inhibit clumping of the protein alpha-synuclein (2/13) |
QBI Life | National Institutes of Health | $0.75 | Roadmap for Medical Research grant | QBI will develop a high-throughput molecular screening platform for membrane protein targets with the universities of Wisconsin and Helsinki (1/19) |
RheoGene Inc.* | Michael J. Fox Foundation for Parkinson's Research | $4.2 | Funding award | RheoGene will use the funds to develop its RheoSwitch Therapeutic System for gene therapy in Parkinson's disease (1/5) |
Semafore | Indiana's 21st Century Research and Technology Fund | $2.27 | Grant | The funds will help the company advance its lead targeted PI3 kinase inhibitor, SF1126, into Phase l trials in solid tumors later in 2006 (3/17) |
Sinovac | China Ministry of Science and Technology | RMB7 ($0.87) | Funding support | The funds will support preclinical trials of Sinovac's Panflu pandemic flu vaccine (12/9) |
Solbec | Australian Industry Department | A$2.26 ($1.66) | AusIndustry Commercial Ready grant | The funds are expected to cover half the cost of the upcoming Phase II trial of the cancer drug Coramsine (12/20) |
Transgene SA | Lyone Biopole Competitive Cluster (France) | €1.3 ($1.6) | Grant | The funds will support development over three years of the vaccine candidate TG4040 for treating hepatitis C (1/25) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
# Item occured before the time frame of this chart but was not included in previous chart. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; TSE = Toronto Stock Exchange. |